{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T18:34:34Z","timestamp":1773945274301,"version":"3.50.1"},"posted":{"date-parts":[[2026,3,19]]},"group-title":"In Review","reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,1,14]]},"abstract":"<title>Abstract<\/title>\n                <p>Frailty predicts adverse outcomes in multiple myeloma (MM), yet an objective frailty biomarker is lacking. Circulating senescence-associated secretory phenotype (SASP) factors correlate with frailty and adverse outcomes in chronic diseases, but their relevance in MM is unclear. In this study, we investigated the relationship between 36 plasma SASP factors, frailty, and clinical outcomes in: (1) a historical cohort using stored specimens from 59 patients with newly diagnosed MM, and (2) a prospective cohort of 36 patients initiating new MM treatment. Several SASP factors were significantly associated with frailty after adjusting for age, sex, and body mass index; GDF-15, TNF-RI, IL-6, and IL-8 showed positive correlations with both cumulative-deficit based and physical frailty indices. Additionally, significant age-adjusted associations were observed between SASP factors and treatment outcomes, including overall survival (OS), high-grade toxicity, and healthcare utilization. We developed a 5-factor SASP model that demonstrated superior predictive performance for OS compared to chronological age, R-ISS stage, and clinical frailty, and TNF-RI alone (5-year OS AUC: 0.90). These findings highlight the association between senescence biomarkers and frailty and OS, and support further investigation of SASP factors as objective frailty biomarkers in MM.<\/p>","DOI":"10.21203\/rs.3.rs-8605152\/v1","type":"posted-content","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:15:07Z","timestamp":1773936907000},"source":"Crossref","is-referenced-by-count":0,"title":["Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple Myeloma"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1589","authenticated-orcid":false,"given":"Nadine","family":"Abdallah","sequence":"first","affiliation":[{"name":"Mayo clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron","family":"Smith","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"White","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Heeren","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Wildes","sequence":"additional","affiliation":[{"name":"Division of Oncology & Hematology, Department of Internal Medicine, University of Nebraska Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-6547","authenticated-orcid":false,"given":"Rosalyn","family":"Marar","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1601-9163","authenticated-orcid":false,"given":"Claire","family":"Yee","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Bodily","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Kotajarvi","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Aug","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Hayman","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7477-3004","authenticated-orcid":false,"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-969X","authenticated-orcid":false,"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"Saurabh","family":"Zanwar","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1576-1534","authenticated-orcid":false,"given":"Jad","family":"Sfeir","sequence":"additional","affiliation":[{"name":"Mayo Clinic College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan","family":"LeBrasseur","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"Mayo clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-0123","authenticated-orcid":false,"given":"Megan","family":"Weivoda","sequence":"additional","affiliation":[{"name":"Mayo Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"13","key":"ref1","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo A","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos M-V, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 2015;125(13):2068\u20132074. DOI: 10.1182\/blood-2014-12-615187.","journal-title":"Blood"},{"issue":"9868","key":"ref2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg A","year":"2013","unstructured":"Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 2013;381(9868):752\u201362. DOI: 10.1016\/S0140-6736(12)62167-9.","journal-title":"Lancet"},{"issue":"5","key":"ref3","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt M","year":"2017","unstructured":"Engelhardt M, Domm AS, Dold SM, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 2017;102(5):910\u2013921. (In eng). DOI: 10.3324\/haematol.2016.162693.","journal-title":"Haematologica"},{"issue":"3","key":"ref4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3324\/haematol.2020.254235","article-title":"Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial","volume":"106","author":"Sandra Maria D","year":"2020","unstructured":"Sandra Maria D, Mandy-Deborah M, Gabriele I, et al. Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial. Haematologica 2020;106(3):875\u2013880. DOI: 10.3324\/haematol.2020.254235.","journal-title":"Haematologica"},{"issue":"3","key":"ref5","doi-asserted-by":"publisher","first-page":"e154-e166","DOI":"10.1016\/s2352-3026(18)30220-5","article-title":"A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study","volume":"6","author":"Cook G","year":"2019","unstructured":"Cook G, Royle KL, Pawlyn C, et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol 2019;6(3):e154-e166. (In eng). DOI: 10.1016\/s2352-3026(18)30220-5.","journal-title":"Lancet Haematol"},{"issue":"11","key":"ref6","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/ajh.24532","article-title":"N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma","volume":"91","author":"Milani P","year":"2016","unstructured":"Milani P, Vincent Rajkumar S, Merlini G, et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol 2016;91(11):1129\u20131134. (In eng). DOI: 10.1002\/ajh.24532.","journal-title":"Am J Hematol"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon T","year":"2020","unstructured":"Facon T, Dimopoulos MA, Meuleman N, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia 2020;34(1):224\u2013233. (In eng). DOI: 10.1038\/s41375-019-0539-0.","journal-title":"Leukemia"},{"issue":"7","key":"ref8","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1038\/s41375-020-0713-4","article-title":"Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities","volume":"34","author":"Stege CAM","year":"2020","unstructured":"Stege CAM, van der Holt B, Dinmohamed AG, et al. Validation of the FIRST simplified frailty scale using the ECOG performance status instead of patient-reported activities. Leukemia 2020;34(7):1964\u20131966. DOI: 10.1038\/s41375-020-0713-4.","journal-title":"Leukemia"},{"issue":"1","key":"ref9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cger.2017.09.004","article-title":"Frailty Screening and Interventions: Considerations for Clinical Practice","volume":"34","author":"Walston J","year":"2018","unstructured":"Walston J, Buta B, Xue QL. Frailty Screening and Interventions: Considerations for Clinical Practice. Clin Geriatr Med 2018;34(1):25\u201338. DOI: 10.1016\/j.cger.2017.09.004.","journal-title":"Clin Geriatr Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.arr.2015.12.003","article-title":"Frailty assessment instruments: Systematic characterization of the uses and contexts of highly-cited instruments","volume":"26","author":"Buta BJ","year":"2016","unstructured":"Buta BJ, Walston JD, Godino JG, et al. Frailty assessment instruments: Systematic characterization of the uses and contexts of highly-cited instruments. Ageing Res Rev 2016;26:53\u201361. (In eng). DOI: 10.1016\/j.arr.2015.12.003.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"ref11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jgo.2013.07.010","article-title":"Patients over 65 years are assigned lower ECOG PS scores than younger patients, although objectively measured physical activity is no different","volume":"5","author":"Broderick JM","year":"2014","unstructured":"Broderick JM, Hussey J, Kennedy MJ, DM OD. Patients over 65 years are assigned lower ECOG PS scores than younger patients, although objectively measured physical activity is no different. J Geriatr Oncol 2014;5(1):49\u201356. DOI: 10.1016\/j.jgo.2013.07.010.","journal-title":"J Geriatr Oncol"},{"issue":"8","key":"ref12","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1002\/cncr.23856","article-title":"Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer","volume":"113","author":"Schnadig ID","year":"2008","unstructured":"Schnadig ID, Fromme EK, Loprinzi CL, et al. Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer. Cancer 2008;113(8):2205\u201314. DOI: 10.1002\/cncr.23856.","journal-title":"Cancer"},{"issue":"5","key":"ref13","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/bloodadvances.2024014624","article-title":"Cumulative deficits frailty index and relationship status predict survival in multiple myeloma","volume":"9","author":"Abdallah N","year":"2025","unstructured":"Abdallah N, Dizona P, Kumar A, et al. Cumulative deficits frailty index and relationship status predict survival in multiple myeloma. Blood Adv 2025;9(5):1137\u20131146. DOI: 10.1182\/bloodadvances.2024014624.","journal-title":"Blood Adv"},{"issue":"4","key":"ref14","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1007\/s11764-024-01591-6","article-title":"Determining the relationship of p16(INK4a) and additional molecular markers of aging with clinical frailty in hematologic malignancy","volume":"18","author":"Rosko AE","year":"2024","unstructured":"Rosko AE, Elsaid MI, Woyach J, et al. Determining the relationship of p16(INK4a) and additional molecular markers of aging with clinical frailty in hematologic malignancy. J Cancer Surviv 2024;18(4):1168\u20131178. (In eng). DOI: 10.1007\/s11764-024-01591-6.","journal-title":"J Cancer Surviv"},{"issue":"22","key":"ref15","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1002\/cncr.33112","article-title":"Accelerated aging among childhood, adolescent, and young adult cancer survivors is evidenced by increased expression of p16INK4a and frailty","volume":"126","author":"Smitherman AB","year":"2020","unstructured":"Smitherman AB, Wood WA, Mitin N, et al. Accelerated aging among childhood, adolescent, and young adult cancer survivors is evidenced by increased expression of p16INK4a and frailty. Cancer 2020;126(22):4975\u20134983. DOI: https:\/\/doi.org\/10.1002\/cncr.33112.","journal-title":"Cancer"},{"issue":"4","key":"ref16","doi-asserted-by":"publisher","first-page":"dju057","DOI":"10.1093\/jnci\/dju057","article-title":"Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer","volume":"106","author":"Sanoff HK","year":"2014","unstructured":"Sanoff HK, Deal AM, Krishnamurthy J, et al. Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst 2014;106(4):dju057. (In eng). DOI: 10.1093\/jnci\/dju057.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"ref17","doi-asserted-by":"publisher","first-page":"e133668","DOI":"10.1172\/jci.insight.133668","article-title":"The senescence-associated secretome as an indicator of age and medical risk","volume":"5","author":"Schafer MJ","year":"2020","unstructured":"Schafer MJ, Zhang X, Kumar A, et al. The senescence-associated secretome as an indicator of age and medical risk. JCI Insight 2020;5(12):e133668. (In eng). DOI: 10.1172\/jci.insight.133668.","journal-title":"JCI Insight"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/biology9120485","article-title":"The Senescence-Associated Secretory Phenotype (SASP) in the Challenging Future of Cancer Therapy and Age-Related Diseases","volume":"9","author":"Cuollo L","year":"2020","unstructured":"Cuollo L, Antonangeli F, Santoni A, Soriani A. The Senescence-Associated Secretory Phenotype (SASP) in the Challenging Future of Cancer Therapy and Age-Related Diseases. Biology 2020;9(12):485. (https:\/\/www.mdpi.com\/2079-7737\/9\/12\/485).","journal-title":"Biology"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"793088","DOI":"10.3389\/fcell.2021.793088","article-title":"Cellular Senescence in Sarcopenia: Possible Mechanisms and Therapeutic Potential","volume":"9","author":"He Y","year":"2021","unstructured":"He Y, Xie W, Li H, Jin H, Zhang Y, Li Y. Cellular Senescence in Sarcopenia: Possible Mechanisms and Therapeutic Potential. Front Cell Dev Biol 2021;9:793088. DOI: 10.3389\/fcell.2021.793088.","journal-title":"Front Cell Dev Biol"},{"key":"ref20","doi-asserted-by":"publisher","author":"Fielding RA","unstructured":"Fielding RA, Atkinson EJ, Aversa Z, et al. Associations between biomarkers of cellular senescence and physical function in humans: observations from the lifestyle interventions for elders (LIFE) study. Geroscience 2022 (In English). DOI: 10.1007\/s11357-022-00685-2.","DOI":"10.1007\/s11357-022-00685-2"},{"key":"ref21","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0. (https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf)."},{"issue":"8","key":"ref22","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and Reliability of the US National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Dueck AC","year":"2015","unstructured":"Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and Reliability of the US National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncology 2015;1(8):1051\u20131059. DOI: 10.1001\/jamaoncol.2015.2639.","journal-title":"JAMA Oncology"},{"issue":"1","key":"ref23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/jgs.18054","article-title":"Patient-reported geriatric assessment-based frailty index among older adults with gastrointestinal malignancies","volume":"71","author":"Giri S","year":"2023","unstructured":"Giri S, Al-Obaidi M, Harmon C, et al. Patient-reported geriatric assessment-based frailty index among older adults with gastrointestinal malignancies. J Am Geriatr Soc 2023;71(1):136\u2013144. (In eng). DOI: 10.1111\/jgs.18054.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"ref24","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1200\/JCO.2010.30.6985","article-title":"Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401","volume":"29","author":"Hurria A","year":"2011","unstructured":"Hurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol 2011;29(10):1290\u20136. DOI: 10.1200\/JCO.2010.30.6985.","journal-title":"J Clin Oncol"},{"issue":"9","key":"ref25","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/cncr.21422","article-title":"Developing a cancer-specific geriatric assessment: a feasibility study","volume":"104","author":"Hurria A","year":"2005","unstructured":"Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 2005;104(9):1998\u20132005. DOI: 10.1002\/cncr.21422.","journal-title":"Cancer"},{"issue":"3","key":"ref26","doi-asserted-by":"publisher","first-page":"M146-56","DOI":"10.1093\/gerona\/56.3.m146","article-title":"Frailty in older adults: evidence for a phenotype","volume":"56","author":"Fried LP","year":"2001","unstructured":"Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56(3):M146-56. (In eng). DOI: 10.1093\/gerona\/56.3.m146.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref27","author":"Schafer MJ","year":"2020","unstructured":"Schafer MJ, Zhang X, Kumar A, et al. The senescence-associated secretome as an indicator of age and medical risk. JCI Insight 2020;5(12) (In English). DOI: ARTN e133668"},{"key":"ref28","unstructured":"1172\/jci.insight.133668."},{"issue":"7","key":"ref29","doi-asserted-by":"publisher","first-page":"e13415","DOI":"10.1111\/acel.13415","article-title":"Exercise reduces circulating biomarkers of cellular senescence in humans","volume":"20","author":"Englund DA","year":"2021","unstructured":"Englund DA, Sakamoto AE, Fritsche CM, et al. Exercise reduces circulating biomarkers of cellular senescence in humans. Aging Cell 2021;20(7):e13415. DOI: https:\/\/doi.org\/10.1111\/acel.13415.","journal-title":"Aging Cell"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"101652","DOI":"10.1016\/j.molmet.2022.101652","article-title":"p21 induces a senescence program and skeletal muscle dysfunction","volume":"2022","author":"Englund DA","unstructured":"Englund DA, Jolliffe A, Aversa Z, et al. p21 induces a senescence program and skeletal muscle dysfunction. Mol Metab 2022:101652. DOI: 10.1016\/j.molmet.2022.101652.","journal-title":"Mol Metab"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1330386","DOI":"10.3389\/fimmu.2024.1330386","article-title":"Level of IL-6, TNF, and IL-1beta and age-related diseases: a systematic review and meta-analysis","volume":"15","author":"Tylutka A","year":"2024","unstructured":"Tylutka A, Walas L, Zembron-Lacny A. Level of IL-6, TNF, and IL-1beta and age-related diseases: a systematic review and meta-analysis. Front Immunol 2024;15:1330386. DOI: 10.3389\/fimmu.2024.1330386.","journal-title":"Front Immunol"},{"issue":"4","key":"ref32","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/gerona\/glab201","article-title":"Associations Between Elevated Growth Differentiation Factor-15 and Sarcopenia Among Community-dwelling Older Adults","volume":"77","author":"Kim M","year":"2022","unstructured":"Kim M, Walston JD, Won CW. Associations Between Elevated Growth Differentiation Factor-15 and Sarcopenia Among Community-dwelling Older Adults. J Gerontol A Biol Sci Med Sci 2022;77(4):770\u2013780. DOI: 10.1093\/gerona\/glab201.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"4026940","DOI":"10.1155\/2022\/4026940","article-title":"A Combination of Serum Biomarkers in Elderly Patients with Sarcopenia: A Cross-Sectional Observational Study","volume":"2022","author":"Ying L","year":"2022","unstructured":"Ying L, Zhang Q, Yang YM, Zhou JY. A Combination of Serum Biomarkers in Elderly Patients with Sarcopenia: A Cross-Sectional Observational Study. Int J Endocrinol 2022;2022:4026940. DOI: 10.1155\/2022\/4026940.","journal-title":"Int J Endocrinol"},{"issue":"3","key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glad265","article-title":"Proteomic Analysis of the Senescence-Associated Secretory Phenotype: GDF-15, IGFBP-2, and Cystatin-C Are Associated With Multiple Aging Traits","volume":"79","author":"Evans DS","year":"2024","unstructured":"Evans DS, Young D, Tanaka T, et al. Proteomic Analysis of the Senescence-Associated Secretory Phenotype: GDF-15, IGFBP-2, and Cystatin-C Are Associated With Multiple Aging Traits. J Gerontol A Biol Sci Med Sci 2024;79(3). DOI: 10.1093\/gerona\/glad265.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"ref35","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41408-023-00843-5","article-title":"Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study","volume":"13","author":"Mian H","year":"2023","unstructured":"Mian H, Wildes TM, Vij R, Pianko MJ, Major A, Fiala MA. Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study. Blood Cancer J 2023;13(1):76. (In eng). DOI: 10.1038\/s41408-023-00843-5.","journal-title":"Blood Cancer J"},{"issue":"5","key":"ref36","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/bloodadvances.2024014624","article-title":"Cumulative deficits frailty index and relationship status predict survival in multiple myeloma","volume":"9","author":"Abdallah N","year":"2025","unstructured":"Abdallah N, Dizona P, Kumar A, et al. Cumulative deficits frailty index and relationship status predict survival in multiple myeloma. Blood Advances 2025;9(5):1137\u20131146. DOI: 10.1182\/bloodadvances.2024014624.","journal-title":"Blood Advances"},{"issue":"5","key":"ref37","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/s41375-025-02572-z","article-title":"Senescence profiling of monoclonal gammopathies reveals paracrine senescence as a crucial defense against disease progression","volume":"39","author":"Borges GA","year":"2025","unstructured":"Borges GA, Diaz-delCastillo M, Guilatco AJ, et al. Senescence profiling of monoclonal gammopathies reveals paracrine senescence as a crucial defense against disease progression. Leukemia 2025;39(5):1206\u20131217. DOI: 10.1038\/s41375-025-02572-z.","journal-title":"Leukemia"},{"issue":"6","key":"ref38","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1158\/0008-5472.Can-11-0188","article-title":"Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma","volume":"72","author":"Corre J","year":"2012","unstructured":"Corre J, Labat E, Espagnolle N, et al. Bioactivity and Prognostic Significance of Growth Differentiation Factor GDF15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma. Cancer Research 2012;72(6):1395\u20131406. DOI: 10.1158\/0008-5472.Can-11-0188.","journal-title":"Cancer Research"},{"issue":"8","key":"ref39","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41591-018-0092-9","article-title":"Senolytics improve physical function and increase lifespan in old age","volume":"24","author":"Xu M","year":"2018","unstructured":"Xu M, Pirtskhalava T, Farr JN, et al. Senolytics improve physical function and increase lifespan in old age. Nature Medicine 2018;24(8):1246\u20131256. DOI: 10.1038\/s41591-018-0092-9.","journal-title":"Nature Medicine"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","article-title":"Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease","volume":"47","author":"Hickson LJ","year":"2019","unstructured":"Hickson LJ, Langhi Prata LGP, Bobart SA, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. Ebiomedicine 2019;47:446\u2013456. DOI: 10.1016\/j.ebiom.2019.08.069.","journal-title":"Ebiomedicine"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.ebiom.2018.12.052","article-title":"Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study","volume":"40","author":"Justice JN","year":"2019","unstructured":"Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. Ebiomedicine 2019;40:554\u2013563. DOI: 10.1016\/j.ebiom.2018.12.052.","journal-title":"Ebiomedicine"},{"issue":"46","key":"ref42","doi-asserted-by":"publisher","first-page":"E6301-10","DOI":"10.1073\/pnas.1515386112","article-title":"JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age","volume":"112","author":"Xu M","year":"2015","unstructured":"Xu M, Tchkonia T, Ding H, et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc Natl Acad Sci U S A 2015;112(46):E6301-10. (In eng). DOI: 10.1073\/pnas.1515386112.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"ref43","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.169512","article-title":"Senotherapeutic drug treatment ameliorates chemotherapy-induced cachexia","volume":"9","author":"Englund DA","year":"2024","unstructured":"Englund DA, Jolliffe AM, Hanson GJ, et al. Senotherapeutic drug treatment ameliorates chemotherapy-induced cachexia. JCI Insight 2024;9(2). DOI: 10.1172\/jci.insight.169512.","journal-title":"JCI Insight"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8605152\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8605152\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:15:08Z","timestamp":1773936908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8605152\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":43,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-8605152\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,3,19]]},"subtype":"preprint"}}